ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

Myofibroblastic cancer-associated fibroblast (myoCAF)–rich tumors generally contain few T cells and respond poorly to immune-checkpoint blockade. Although myoCAFs are associated with poor outcome in most solid tumors, the molecular mechanisms regulating myoCAF accumulation remain unclear, limiting t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mellone, Massimiliano, Piotrowska, Klaudia, Venturi, Giulia, James, Lija, Bzura, Aleksandra, Lopez, Maria A., James, Sonya, Wang, Chuan, Ellis, Matthew J., Hanley, Christopher J., Buckingham, Josephine F., Cox, Kerry L., Hughes, Gareth, Valge-Archer, Viia, King, Emma V., Beers, Stephen A., Jaquet, Vincent, Jones, George D.D., Savelyeva, Natalia, Sayan, Emre, Parsons, Jason L., Durant, Stephen, Thomas, Gareth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Tumor Biology and Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755965/
https://www.ncbi.nlm.nih.gov/pubmed/36353752
http://dx.doi.org/10.1158/0008-5472.CAN-22-0435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755965/
https://www.ncbi.nlm.nih.gov/pubmed/36353752
http://dx.doi.org/10.1158/0008-5472.CAN-22-0435

Ejemplares similares